Oric Pharmaceuticals Inc. (ORIC)
| Market Cap | 1.28B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 30.31M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $36.09 |
| Previous Close | $36.09 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 33.50 |
| Day's Range | 32.47 - 36.38 |
| Day's Volume | 1,087,343 |
| 52-Week Range | 19.50 - 39.80 |
Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...
Initiated Part II expansion of the Phase 1b study of ORIC-101 in combination with Abraxane (nab-paclitaxel) using recommended Phase 2 dose selected from Part I of the study
ORIC Pharmaceuticals (ORIC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
About ORIC
ORIC Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also develo... [Read more...]
| Industry Biotechnology | IPO Date Apr 24, 2020 |
| CEO Jacob Chacko | Employees 60 |
| Stock Exchange NASDAQ | Ticker Symbol ORIC |
Analyst Forecasts
According to 7 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price forecast is 44.14, which is an increase of 22.31% from the latest price.